New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
September 18, 2017 – Optinose announced the FDA approval of Xhance (fluticasone propionate) for the treatment of nasal polyps in patients 18 years of age or older.
Download PDF
Return to publications
